Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Study Evaluating Genetically Modified Autologous T Cells Expressing a TCR Recognizing a Cancer/Germline Antigen as Monotherapy or in Combination With Nivolumab in Patients With Recurrent and/or Refractory Solid Tumors

NCT03686124 is registered in ClinicalTrials.gov with Immatics US, Inc. as lead sponsor.

NCT NCT03686124
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03686124 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Study Evaluating Genetically Modified Autologous T Cells Expressing a TCR Recognizing a Cancer/Germline Antigen as Monotherapy or in Combination With Nivolumab in Patients With Recurrent and/or Refractory Solid Tumors
Lead sponsor
Immatics US, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 14, 2019
Completion date
June 30, 2032
Enrollment
375 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, recurrent cancer, refractory cancer, solid tumor, adult